As of November 6, 2026, Neogenomics, Inc. is a publicly traded company (Nasdaq: NEO); its largest reported holder is BlackRock, with 15.6% on Schedule 13G/A of July 30, 2026, then Mathew P. Arens (8.37%). The largest insider holding is Christopher M. Smith, the chief executive, with 641,585 shares (0.50% of shares outstanding), per Form 4 of February 25, 2025 (Schedule 13G/A, July 30, 2026).
Is this your company?
About to sign with, pay or invest in Neogenomics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Neogenomics, Inc. a real, registered company?
- Neogenomics, Inc. files with the SEC under CIK 1077183 (its SEC filings).
- Its shares are listed under the ticker NEO on Nasdaq (SEC company record).
- Incorporated in Nevada; business address in Fort Myers, Florida, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Neogenomics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Lynn Tetrault, Chair of the Board (Form 8-K filed 2026-10-05). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Mathew P. Arens (filed 2026-08-14).
Who are Neogenomics, Inc.'s owners and officers?
Neogenomics, Inc.: incorporated in Nevada; business address in Fort Myers, Florida; industry Services-Testing Laboratories (Form D, 2026-10-05).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Mathew P. Arens | 8.37% |
| Schedule 13G/A, 2026-07-30 | Blackrock, Inc. | 15.6% |
| Schedule 13G, 2026-07-30 | First Trust Portfolios L.P. | 7.77% |
| Schedule 13G/A, 2026-05-15 | Greenhouse Funds Lllp | 7.1% |
| Schedule 13G/A, 2026-05-13 | Millennium Management LLC | 1.7% |
| Schedule 13G/A, 2026-05-07 | Mathew P. Arens | 10.82% |
| Schedule 13G, 2026-04-30 | Vanguard Capital Management | 5.09% |
| Schedule 13G, 2026-04-29 | Vanguard Portfolio Management | 5.91% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13G, 2025-12-09 | Millennium Management LLC | 5% |
| Schedule 13G, 2025-12-02 | Millennium Management LLC | 4.97% |
| Schedule 13G/A, 2025-10-17 | Blackrock, Inc. | 14.6% |
Questions about who owns Neogenomics, Inc.
Who owns Neogenomics, Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Neogenomics, Inc.: Blackrock, Inc. (15.6%, Schedule 13G/A, filed 2026-07-30), Mathew P. Arens (8.37%, Schedule 13G/A, filed 2026-08-14), First Trust Portfolios L.P. (7.77%, Schedule 13G, filed 2026-07-30), Greenhouse Funds Lllp (7.1%, Schedule 13G/A, filed 2026-05-15) and Vanguard Portfolio Management (5.91%, Schedule 13G, filed 2026-04-29); 1 more is listed above.
Who are the largest shareholders of Neogenomics, Inc.?
By the share each holder's latest filing reports, the largest holders of Neogenomics, Inc. on this page are Blackrock, Inc. (15.6%), Mathew P. Arens (8.37%) and First Trust Portfolios L.P. (7.77%).
When did Blackrock, Inc. buy into Neogenomics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Blackrock, Inc. on this page is the Schedule 13G/A, filed 2025-10-17, reporting 14.6%; its latest, Schedule 13G/A filed 2026-07-30, reports 15.6%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Neogenomics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Neogenomics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Neogenomics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
20 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-10-05 | Lynn Tetrault | Chair of the Board | departed | 2027-01-04 |
| Form 8-K, 2026-06-25 | Carolyn S. Starrett | Director | appointed |
Which insiders own Neogenomics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive: 641,585 shares (0.50% of shares outstanding) (Form 4, 2025-02-25).
- , the chief financial officer: 220,009 shares (0.17% of shares outstanding) (Form 4, 2026-02-24).
- , the president and chief operating officer: 191,729 shares (0.15% of shares outstanding) (Form 4, 2026-10-05).
- , the chief executive and a director: 152,011 shares (0.12% of shares outstanding), 133,111 held directly and 18,900 indirectly (Form 4, 2026-04-03).
- , a director: 131,023 shares (0.10% of shares outstanding) (Form 4/A, 2025-06-03).
Shares outstanding: 129,389,465 as of 2026-10-23, from the company's latest SEC cover page.
How much has Neogenomics, Inc. raised?
No fundraising or offering filing from Neogenomics, Inc. is on file with us.
Keep reading
More on Neogenomics, Inc. and the records around it.
Neogenomics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Leadership changes Aug 2026
Companies that share a holder
- Greenhouse Funds LLLP also filed stake reports on 5 other companies: NCR Voyix Corp (Sep 2026), Clarus Corporation (May 2026), PHREESIA, INC. (Feb 2026)
- First Light Asset Management, LLC also filed stake reports on 12 other companies: NeuroPace Inc (Sep 2026), PALVELLA THERAPEUTICS, INC. (Aug 2026), TriSalus Life Sciences, Inc. (Jul 2026)
- Integrated Core Strategies (US) LLC also filed stake reports on 63 other companies: SkinHealth Systems Inc. (Nov 2026), Infinite Eagle Acquisition Corp. (Nov 2026), Longeveron Inc. (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/neogenomics